Evaluating factors that predict breast cancer spread to bones
Evaluation of Prognostic Factors: From Breast Cancer to Bone Metastases
This study is trying to find out if a protein called SENP1 can help predict how likely breast cancer is to spread to the bones, which could help doctors better treat patients at risk.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio Academic / other |
| Locations | 1 site (Milan) |
| Trial ID | NCT04167605 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on understanding the mechanisms behind the spread of breast cancer to bone, a common complication that significantly impacts patient quality of life. Researchers aim to identify prognostic factors, particularly the role of SENP1, a protein involved in post-translational modifications, in the progression of breast cancer and its metastasis to bone. By evaluating the expression of SENP1 in both metastatic and non-metastatic breast cancer cases, the study seeks to uncover predictive indicators that could inform therapeutic strategies for high-risk patients. The ultimate goal is to improve outcomes for patients with breast cancer who are at risk of developing bone metastases.
Who should consider this trial
Good fit: Ideal candidates are adult women aged 18 and older with breast cancer who are undergoing surgery for osteolytic bone metastases.
Not a fit: Patients who do not have breast cancer or those who are not candidates for surgery due to other health issues may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better identification of patients at high risk for bone metastases and inform targeted therapeutic strategies.
How similar studies have performed: While there have been studies focusing on breast cancer metastasis, the specific investigation of SENP1 as a prognostic factor is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult women (≥ 18 years) candidates for excisional surgery and bone consolidation due to osteolytic bone metastases from breast cancer. * Female * Ability to understand the experimental study and willingness to sign the written consent Exclusion Criteria: - Retraction of written consent
Where this trial is running
Milan
- IRCCS Istituto Ortopedico Galeazzi — Milan, Italy (Recruiting)
Study contacts
- Study coordinator: Paola Maroni, PhD
- Email: paola.maroni@grupposandonato.it
- Phone: +39 026621
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.